Melanotan II

Research

Melanotan II

Aliases
MT-2, MT-II
Administration
Subcutaneous injection (unregulated, self-administered)

Research and regulatory

Development stage

No FDA clinical development pathway for tanning; a related but distinct molecule (bremelanotide/PT-141) was separately developed and approved for sexual dysfunction.

Legal and regulatory

Unscheduled research compound; not FDA approved for any indication and widely sold illicitly for cosmetic tanning.

Side effects

Nausea (common, especially early doses), flushing, spontaneous erections, darkening of existing moles, appetite suppression